Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
Share Market News
ASX 200 lunch time report: Afterpay, Resolute, & Westpac higher
Share Market News
4 of the biggest news pieces from the ASX200 this week
Share Gainers
These were the best-performing shares on the ASX 200 last week
Share Gainers
ALL ORDINARIES finishes higher Friday: 8 ASX shares you missed
Share Fallers
Why BWX, Creso Pharma, Mayne Pharma, & St Barbara shares dropped lower
Share Market News
ASX 200 lunch time report: NAB lower, CSL & Nearmap higher
Share Gainers
ALL ORDINARIES finishes lower Thursday: 8 ASX shares you missed
Share Gainers
Why this ASX healthcare stock shot 18% higher yesterday
Share Gainers
ALL ORDINARIES finishes lower Wednesday: 8 ASX shares you missed
Share Gainers
Why Afterpay, Clinuvel, Mayne Pharma, & ResApp shares charged higher today
Share Market News
ASX 200 lunch time report: Bega Cheese & NAB lower, Mayne Pharma rockets
Share Market News
Mayne Pharma shares on watch after major agreement with Mithra Pharmaceuticals
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
